Onconetix, Inc.

ONCO Healthcare Biotechnology

Onconetix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $815,400.00, down 67.7% from fiscal 2024. In the quarter to June 2026, revenue fell 83.9%, EPS grew 99.5% and free cash flow fell 36.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.48 0.07 −12.73%
Market cap
$2.9M
P/E
0.0×
Fwd P/E
−8.7×
Dividend yield
—
F-score
5/9
Altman Z
−9.75
Beneish M
33.30
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(229.05%) (127.79%) (127.45%) (105.23%)
ROA
(124.62%) (58.49%) (59.69%) (57.37%)
ROIC
(1,126.14%) (105.85%) (120.73%) (135.42%)
Return on Tangible Assets
339.86% 512.23% (774.32%) (283.02%)
Average Days of Receivables
0.78 155.28 21.69 1.36
Free Cash Flow per Share
(267.10) (514.81) (155.81) (4.60)
Free Cash Flow
(7.51) (9.68) (9.80) (10.31)
Other line items

Show all line items

Columns are period end dates